Trevi Therapeutics, Inc. Impairment of Long-Lived Assets Held-for-use
Trevi Therapeutics, Inc. (TRVI) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2023-03-16
- Trevi Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- Trevi Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- Trevi Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
- Trevi Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2019 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-16 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-17 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |